According to OPKO Health 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.968612. At the end of 2023 the company had a P/S ratio of 1.35.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.35 | 40.55% |
2022 | 0.9618 | -47.91% |
2021 | 1.85 | 0.16% |
2020 | 1.84 | 68.88% |
2019 | 1.09 | -38.74% |
2018 | 1.78 | -35.06% |
2017 | 2.74 | -35.33% |
2016 | 4.24 | -61.9% |
2015 | 11.1 | -76.49% |
2014 | 47.4 | 31.35% |
2013 | 36.1 | 15.46% |
2012 | 31.2 | -38.54% |
2011 | 50.8 | 89.59% |
2010 | 26.8 | -24.09% |
2009 | 35.3 | 3.57% |
2008 | 34.1 | |
2003 | 58.6 | 824.51% |
2002 | 6.34 | -84.32% |
2001 | 40.4 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.10 | 323.08% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 4.92 | 407.65% | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | 8.09 | 735.55% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 2.44 | 151.56% | ๐บ๐ธ USA |
LabCorp LH | 1.42 | 47.02% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | 10.3 | 962.88% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 0.9982 | 3.05% | ๐ฎ๐ฑ Israel |
Ardelyx ARDX | 13.6 | 1,309.06% | ๐บ๐ธ USA |